免疫检查点抑制剂市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球免疫检查点抑制剂市场达到474 亿美元，预计2024 年至2032 年复合年增长率为16.7%。 。免疫检查点抑制剂增强免疫系统针对癌细胞的能力，对黑色素瘤、肺癌和肾细胞癌有效。广泛的临床试验、有利的监管批准以及与治疗方案的整合支持了市场扩张。对肿瘤学研究的投资增加和新抑制剂的强大管道维持了市场成长。例如，2021年7月，兰金政府投资1,800万美元用于癌症治疗，包括免疫检查点抑制剂。 2023年，癌症研究所拨款2,800万美元用于癌症免疫治疗研究。政府和组织实体的这种支持对于市场成长至关重要。

整个免疫检查点抑制剂行业根据类型、应用、最终用途和地区进行分类。

免疫检查点抑制剂阻断称为检查点的蛋白质，增强免疫细胞攻击癌细胞的能力。市场按类型分类：PD-L1、CTLA-4、PD-1 等。 PD-1 细分市场在 2023 年占据主导地位，销售额为 347 亿美元。 PD-1 抑制剂，如纳武单抗和派姆单抗，在多种癌症中显示出令人印象深刻的疗效，包括非小细胞肺癌、黑色素瘤和肾细胞癌。稳健的临床结果和肿瘤学实践中不断增长的采用巩固了 PD-1 抑制剂的领先市场地位。

市场按应用细分为黑色素瘤、乳癌、肺癌、膀胱癌、何杰金氏淋巴瘤、子宫颈癌、大肠直肠癌等。 2023 年，肺癌占首位，占 25.1%。肺癌的巨大负担和这些疗法已被证实的疗效可提高患者的治疗效果。 2023年，美国新诊断出238,340例肺癌，约127,070人死亡。针对 PD-1、PD-L1 和 CTLA-4 的免疫检查点抑制剂已在治疗非小细胞肺癌 (NSCLC) 方面取得了成功。正在进行的研究和临床试验正在扩大这些抑制剂在不同肺癌阶段的应用。

2023年，北美市场占有率为229亿美元，预计2024年至2032年复合年增长率为16.8%。美国癌症协会估计，2024 年美国和加拿大将新增约 2,170,450 例癌症病例，凸显了对先进癌症疗法的需求。此外，政府对癌症研究和治疗的资助增加进一步推动了该地区市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球癌症发生率不断上升
    • 免疫疗法的持续研究和开发
    • 有利的监管环境
    • 增加投资和伙伴关係
  • 产业陷阱与挑战
    • 治疗费用高
    • 不良副作用
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• PD-1
• PD-L1
• CTLA-4
• 其他类型

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 肺癌
• 乳癌
• 膀胱癌
• 黑色素瘤
• 子宫颈癌
• 霍奇金淋巴瘤
• 大肠直肠癌
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 癌症中心
• 学术及研究机构

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AstraZeneca PLC
• BeiGene, Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Incyte Corporation
• Immutep Limited
• Merck and Co., Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Shanghai Junshi Biosciences Co., Ltd.

The Global Immune Checkpoint Inhibitors Market reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032. This growth is driven by the rising global cancer prevalence and demand for advanced, personalized therapies. Immune checkpoint inhibitors enhance the immune system's ability to target cancer cells, showing effectiveness against melanoma, lung cancer, and renal cell carcinoma. Extensive clinical trials, favorable regulatory approvals, and integration into treatment protocols support market expansion. Increased investments in oncology research and a strong pipeline of new inhibitors sustain market growth. For instance, in July 2021, the Rankin government invested USD 18 million in cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million for cancer immunotherapy research. Such support from governmental and organizational entities is crucial for market growth.

The overall immune checkpoint inhibitors industry is classified based on the type, application, end-use, and region.

Immune checkpoint inhibitors block proteins known as checkpoints, enhancing immune cells' ability to attack cancer cells. The market is categorized by type: PD-L1, CTLA-4, PD-1, and others. The PD-1 segment dominated in 2023 with USD 34.7 billion. PD-1 inhibitors, like nivolumab and pembrolizumab, show impressive efficacy across various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Robust clinical outcomes and growing adoption within oncology practices reinforce the leading market position of PD-1 inhibitors.

The market is segmented by application into melanoma, breast cancer, lung cancer, bladder cancer, Hodgkin lymphoma, cervical cancer, colorectal cancer, and others. In 2023, lung cancer led with a 25.1% share. Lung cancer's significant burden and the proven efficacy of these therapies enhance patient outcomes. In 2023, the U.S. saw 238,340 new lung cancer diagnoses, with approximately 127,070 fatalities. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown success in treating non-small cell lung cancer (NSCLC). Ongoing research and clinical trials are broadening the application of these inhibitors across various lung cancer stages.

In 2023, North America held a USD 22.9 billion share of the market, with a projected CAGR of 16.8% from 2024 to 2032. The presence of leading pharmaceutical companies and a favorable regulatory landscape bolster the North American market. The American Cancer Society estimates around 2,170,450 new cancer cases in the U.S. and Canada in 2024, highlighting the demand for advanced cancer therapies. Additionally, increasing government funding for cancer research and treatment is further driving the market's growth in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cancer incidence across the world
    • 3.2.1.2 Ongoing research and development in immunotherapy
    • 3.2.1.3 Favorable regulatory environment
    • 3.2.1.4 Increasing investments and partnerships
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 PD-1
• 5.3 PD-L1
• 5.4 CTLA-4
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Bladder cancer
• 6.5 Melanoma
• 6.6 Cervical cancer
• 6.7 Hodgkin lymphoma
• 6.8 Colorectal cancer
• 6.9 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Cancer centers
• 7.4 Academic and research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca PLC
• 9.2 BeiGene, Ltd.
• 9.3 Bristol-Myers Squibb Company
• 9.4 Eli Lilly and Company
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 GlaxoSmithKline plc
• 9.7 Incyte Corporation
• 9.8 Immutep Limited
• 9.9 Merck and Co., Inc.
• 9.10 Regeneron Pharmaceuticals, Inc.
• 9.11 Sanofi
• 9.12 Shanghai Junshi Biosciences Co., Ltd.